ESR1 and breast cancer: Triple-negative breast cancer (TNBC) represents approximately 15–20% of all breast cancers that clinically are negative for the expression of estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) proteins [3].